Guidelines for Waiting Periods Between Imaging Procedures Performed Before MBI Examination

ModalityProcedureAdministered doseRecommended waiting period
CTWith or without contrastNone
MRIWith or without contrastNone
PET18F-FDG555 MBq (15 mCi)>12 h
11C-choline370–740 MBq (10–20 mCi)>2 h
13N-ammonia370–740 MBq (10–20 mCi)>1 h
Nuclear medicine99mTc-sestamibi for parathyroid or cardiac studies370–1,110 MBq (10–30 mCi)None*
99mTc-radiopharmaceuticals, intravenous>740 MBq (20 mCi)>24 h
>370 MBq (10 mCi)>18 h
>185 MBq (5 mCi)>12 h
<185 MBq (5 mCi)>6 h
99mTc-radiopharmaceuticals, oral<185 MBq (5 mCi)None
123I-based radiopharmaceuticals>370 MBq (10 mCi)>2 d
111In- and 67Ga-based radiopharmaceuticals185–370 MBq (5–10 mCi)>3 d
<37 MBq (1 mCi)>24 h
  • These are general guidelines and in some cases may overestimate waiting period needed, depending on biologic distribution of radiopharmaceutical.

  • * In cases of prior administration of 99mTc-sestamibi for cardiac or parathyroid studies, reduced (or no dose) of 99mTc-sestamibi may be used, depending on residual activity from prior study.